Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 3Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Breast Neoplasms 186Carcinoma, Non-Small-Cell Lung 144Multiple Myeloma 120Prostatic Neoplasms 118Leukemia, Myeloid, Acute 77Neoplasms 75Colorectal Neoplasms 75Melanoma 72Neoplasm Metastasis 66Lymphoma 66Squamous Cell Carcinoma of Head and Neck 64Lung Neoplasms 64Pancreatic Neoplasms 54Ovarian Neoplasms 50Sarcoma 46Carcinoma, Renal Cell 45Triple Negative Breast Neoplasms 43Glioblastoma 42Urinary Bladder Neoplasms 41Leukemia, Lymphocytic, Chronic, B-Cell 41Carcinoma, Hepatocellular 41Recurrence 40Head and Neck Neoplasms 38Hematologic Neoplasms 37Lymphoma, Large B-Cell, Diffuse 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Myelodysplastic Syndromes 35Lymphoma, Non-Hodgkin 34Brain Neoplasms 34Lymphoma, Mantle-Cell 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Immunologic Deficiency Syndromes × Clear all
NCT04554914 2026-04-27

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Pierre Fabre Medicament

Phase 2 Active not recruiting
190 enrolled
LymphoidSarcoma

Immunologic Deficiency Syndromes, Leiomyosarcoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡